Ischemic heart disease II Flashcards
ACS acute supportive care (MONA)
Morphine
* Oxygen
* Nitroglycerin
* Aspirin
ACS acute supportive care (THROMINS acronym)
Thienopyridine (clopidogrel)
* Heparin
* RAAS
* Oxygen
* Morphine
* B-blocker
* Intervention
* Nitroglycerin
* Statin/salicylate
Initial management of unstable ANGINA PECTORIS &
NSTEMI
Oxygen 40% via facemask, if saturation < 94% or if in distress.
* Aspirin, oral, 150 mg as a single dose (chewed or dissolved) as soon as
possible.
* ADD
* Nitrates, short acting, e.g.: isosorbide dinitrate, sublingual, 5 mg
immediately as a single dose.
* May be repeated at 5-minute intervals for 3 or 4 doses.
* ADD
* Morphine 10 mg diluted with 10 mL of water for injection or sodium
chloride 0.9%, slow IV (Doctor prescribed).
* Start with 5 mg; thereafter slowly increase by 1 mg/minute up to 10 mg.
* Can be repeated after 4–6 hours if necessary, for pain relief.
* Beware of hypotension.
Initial management of unstable acute MI & STEMI
Before transfer: cardiopulmonary resuscitation if necessary
* Oxygen 40% via facemask, if saturation < 94% or if in distress.
* Aspirin, oral, 150 mg as a single dose (chewed or dissolved) as soon as possible.
* AND
* Nitrates, short acting, e.g.: isosorbide dinitrate, sublingual, 5 mg immediately as a
single dose.
* May be repeated at 5-minute intervals for 3 or 4 doses.
* AND
* Morphine 10 mg diluted with 10 mL of water for injection or sodium chloride 0.9%,
slow IV (Doctor prescribed).
* Start with 5 mg; thereafter slowly increase by 1 mg/minute up to 10 mg.
* Can be repeated after 4–6 hours if necessary, for pain relief.
* Beware of hypotension.
* AND (if patient qualify)
* Thrombolytic: streptokinase OR if unavailable alteplase
Indications of thrombolytic therapy (5)
For acute myocardial infarction with ST
elevation or left bundle branch block:
* maximal chest pain is ≤6 hours
* beyond 6 hours and chest pain, consult a
specialist
* >6 hours and no chest pain, manage with
anticoagulants
* if on-going ischaemic pain
Contra-indications of thrombolytic therapy
Absolute:
* streptokinase used within the last year, (not for alteplase)
* previous allergy,
* CVA within the last 3 months,
* history of recent major trauma,
* bleeding within the last month,
* aneurysms,
* brain or spinal surgery or head injury within the preceding
month, or recent (<3 weeks) major surgery,
* active bleeding or known bleeding disorder,
What to monitor after administration of thrombolytic therapy? 4
Pulse
* BP
* Respiration depth and rate (count for a full minute)
* ECG
Antiplatelet tx (2)
Clopidogrel
* Aspirin, oral, 150 mg stat, then as daily single dose, continued
indefinitely in the absence of contraindications
MOA of aspirin
Provides its antiplatelet effect by acetylating a hydroxyl group of
serine 530 on the cyclooxygenase (COX) 1 enzyme on platelets and
thereby preventing the conversion of arachidonic acid into
prostaglandins, and eventually thromboxane A2.
Function of thromboxane A2
Thromboxane A2 produces platelet activation as well as
vasoconstriction.
Discuss half life of aspirin
- While unbound aspirin has a half-life of only about 15 to 20 minutes,
the irreversible binding of aspirin to the platelet COX1 enzyme
inhibits thromboxane A2–induced platelet activation for the life of
the platelet (7 - 10 days).
Explain why low dose daily aspirin therapy is preferred than high dose
After the initial dose of aspirin, daily doses of aspirin should be
continued indefinitely.
* Higher daily maintenance doses of aspirin (300- 325 mg) do not
reduce CV death, MI, or stroke compared to lower daily maintenance
doses (75 – 100 mg), but significantly increase the incidence of
gastrointestinal (GI) bleeding.
Contraindications of aspirin 2
Hypersensitivity
GI intolerance
Aspirin is often used in combination with what in ACS?
s typically combined with an oral P2Y12 inhibitor (clopidogrel) as part of
dual antiplatelet therapy (DAPT).
How does P2Y12 inhibitor work?
P2Y12 receptor irreversible bond and prevents the receptor’s ability
to be activated by adenosine diphosphate and subsequent platelet
activation and aggregation.